For instance, while TP53 is significantly enriched for mutations in ovarian, colorectal, head and neck, or lung cancers, it is mutated below expectations – set by other driver TFs – in thyhroid and prostate carcinomas, as well as in melanomas and medulloblastomas. This evidence concerns the gene TP53 and medulloblastoma.